- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- NPH and regular insulin, glargine and humalog
- Drug
- Lead sponsor
- Riverside University Health System Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Moreno Valley, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 3,593
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- 2nd Gen LabPatch Glucose Sensing System
- Device
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 14 Years to 50 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Type 2 Diabetes
- Interventions
- Saxagliptin, Metformin XR, Dapagliflozin, Placebo matching with Dapagliflozin, Placebo matching with Saxagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canagliflozin, Placebo, Sitagliptin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 678 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more
- Conditions
- Congenital Heart Disease, Viremia, Virus Diseases, Enterovirus, Enterovirus Infections, Heart Defects, Congenital, Heart Diseases, Prenatal Infection, Diabetes, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy Complications, Prenatal
- Interventions
- Stool and Blood Specimen Collection, Follow-up Medical Record Review
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- St Louis, Missouri
- Conditions
- Diabetes Mellitus, Type 2, Insulin Resistance, Glucose Intolerance, Sleep Disturbance, Overweight or Obesity, Insulin Sensitivity
- Interventions
- Resistance Exercise Timing
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 50 Years to 74 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg, DEN 30 mg, DEN 45 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 36
- States / cities
- Long Beach, California • Pasadena, California • Denver, Colorado + 32 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2, PF-04937319 MR 3
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- High Point, North Carolina • San Antonio, Texas
- Conditions
- Prediabetes, Type 2 Diabetes
- Interventions
- Metformin, Glargine
- Drug
- Lead sponsor
- RISE Study Group
- Network
- Eligibility
- 10 Years to 19 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 4
- States / cities
- Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 1 more
- Conditions
- Obesity, Overweight
- Interventions
- NB32, PBO, Weight Management Program
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 8,910 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 224
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
- Conditions
- Type 2 Diabetes
- Interventions
- Whole Fruit
- Other
- Lead sponsor
- Harvard School of Public Health (HSPH)
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 112
- States / cities
- Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Not listed
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 874 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fresno, California + 12 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BT-001, Control App
- Behavioral · Other
- Lead sponsor
- Better Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • New Orleans, Louisiana • Durham, North Carolina
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- Kerendia (Finerenone, BAY94-8862)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 38
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Harrisburg, Arkansas + 33 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 37
- States / cities
- Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Metformin, Ranolazine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Coronavirus Infection, Type 2 Diabetes
- Interventions
- Linagliptin, Insulin regimen
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
- Interventions
- Polygenic risk score (PRS)
- Diagnostic Test
- Lead sponsor
- Boston VA Research Institute, Inc.
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 1,071 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina
- Other
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Not listed
- Lead sponsor
- Wyckoff Heights Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults
- Interventions
- Calcium-HMB Plus Vitamin D3, Matching placebo
- Dietary Supplement · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 2 Diabetes
- Interventions
- Enhanced Telemedicine for Type 2 Diabetes, Usual Telemedicine Endocrinology Care for T2D
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania